First Acellular DTP Vaccine Licensed For Infants In USA
The US Food and Drug Administration has licensed the first acellular pertussis vaccine, Connaught Laboratories' Tripedia (DTPa), for use in the primary vaccination of infants and children two months of age and older in the USA. The vaccine protects infants against whooping cough while causing fewer side-effects than whole-cell pertussis vaccines currently on the market.
Currently, children in the USA receive a whole-cell vaccine in combination with diphtheria-tetanus toxoid (DTP), at two, four and six months of age, with boosters of either a whole-cell DTP or DTPa at 12-18 months and before going to school.
Tripedia is one of two DTPa vaccines already approved for children to be given as fourth and fifth doses following three whole-cell DTP doses. The vaccine beats at least three competitors to become the USA's first primary acellular pertussis vaccine, including SmithKline Beecham's Infanrix. It will cost around $17 per dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze